In early results “unprecedented in rectal cancer,” 14/14 patients show clinical complete response to dostarlimab

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

All fourteen rectal cancer patients in a small phase II study of dostarlimab, an anti-PD-1 monoclonal antibody, saw their cancer completely disappear—with no progression or recurrence at follow-up six to 25 months later. None of the patients required further chemotherapy, radiation, or surgery. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Alice Tracey
Alice Tracey
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Noetik and Memorial Sloan Kettering Cancer Center have partnered to advance the next generation of cancer biology world models. The collaboration brings together MSK’s depth of oncology expertise and research resources with Noetik’s AI and data foundry capabilities to enable a more diverse and comprehensive model view of cancer development and enhance clinical outcomes.
At the recommended regimen, 73% of patients receiving a pasritamig and JNJ-9401 combination, two bispecific antibodies designed to work together to drive the body’s immune response against advanced prostate cancer, achieved reductions of at least 50% in prostate-specific antigen, according to the results of a first-in-human phase I study. 
I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.
Alice Tracey
Alice Tracey
Reporter

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login